Related references
Note: Only part of the references are listed.The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands
Adam J. Pawson et al.
NUCLEIC ACIDS RESEARCH (2014)
Antitumor Action of a Novel Histone Deacetylase Inhibitor, YF479, in Breast Cancer
Tao Zhang et al.
NEOPLASIA (2014)
THE CONCISE GUIDE TO PHARMACOLOGY 2013/14: CATALYTIC RECEPTORS
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
THE CONCISE GUIDE TO PHARMACOLOGY 2013/14: ENZYMES
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Cucurbitacin E inhibits breast tumor metastasis by suppressing cell migration and invasion
Tao Zhang et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Role of epidermal growth factor receptor in breast cancer
Hiroko Masuda et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks
Michael J. Lee et al.
CELL (2012)
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
Omar Khan et al.
IMMUNOLOGY AND CELL BIOLOGY (2012)
TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
Lisa A. Carey et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A Natural Small Molecule Harmine Inhibits Angiogenesis and Suppresses Tumour Growth through Activation of p53 in Endothelial Cells
Fujun Dai et al.
PLOS ONE (2012)
Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
Chandra R. Tate et al.
BREAST CANCER RESEARCH (2012)
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
P. N. Munster et al.
BRITISH JOURNAL OF CANCER (2011)
Discovery of a Tetrahydroisoquinoline-Based Hydroxamic Acid Derivative (ZYJ-34c) as Histone Deacetylase Inhibitor with Potent Oral Antitumor Activities
Yingjie Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Feedback regulation of EGFR signalling: decision making by early and delayed loops
Roi Avraham et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2011)
HDAC Inhibition Decreases the Expression of EGFR in Colorectal Cancer Cells
Chia-Wei Chou et al.
PLOS ONE (2011)
Towards a Functional Understanding of Protein N-Terminal Acetylation
Thomas Arnesen
PLOS BIOLOGY (2011)
Epigenetics in breast cancer: what's new?
Yi Huang et al.
BREAST CANCER RESEARCH (2011)
Guidelines for reporting experiments involving animals: the ARRIVE guidelines
J. C. McGrath et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Carol Kilkenny et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Detection of Elevated Plasma Levels of Epidermal Growth Factor Receptor Before Breast Cancer Diagnosis among Hormone Therapy Users
Sharon J. Pitteri et al.
CANCER RESEARCH (2010)
Cucurbitacin E, a tetracyclic triterpenes compound from Chinese medicine, inhibits tumor angiogenesis through VEGFR2-mediated Jak2-STAT3 signaling pathway
Yanmin Dong et al.
CARCINOGENESIS (2010)
Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line
Jennifer S. Waby et al.
MOLECULAR CANCER (2010)
Understanding resistance to EGFR inhibitors-impact on future treatment strategies
Deric L. Wheeler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
B. Corkery et al.
ANNALS OF ONCOLOGY (2009)
Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells
Qun Zhou et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
14-3-3ζ Cooperates with ErbB2 to Promote Ductal Carcinoma In Situ Progression to Invasive Breast Cancer by Inducing Epithelial-Mesenchymal Transition
Jing Lu et al.
CANCER CELL (2009)
Cytotoxicity Mediated by Histone Deacetylase Inhibitors in Cancer Cells: Mechanisms and Potential Clinical Implications
David S. Schrump
CLINICAL CANCER RESEARCH (2009)
Rational Combinations Using HDAC Inhibitors
Michael Bots et al.
CLINICAL CANCER RESEARCH (2009)
Sp1 Phosphorylation and Its Regulation of Gene Transcription
Nicole Y. Tan et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Attenuation of c-Jun and Sp1 expression and p300 recruitment to gene promoter confers the trichostatin A-induced inhibition of 12(S)-lipoxygenase expression in EGF-treated A431 cells
Ching-Jiunn Chen et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Histone deacetylase 7 silencing alters endothelial cell migration, a key step in angiogenesis
Denis Mottet et al.
CIRCULATION RESEARCH (2007)
Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator
Sai Murali Krishna Pulukuri et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Histone deacetylase inhibitors: molecular mechanisms of action
W. S. Xu et al.
ONCOGENE (2007)
Three-dimensional culture models of normal and malignant breast epithelial cells
Genee Y. Lee et al.
NATURE METHODS (2007)
Cancer epigenomics: DNA methylomes and histone-modification maps
Manel Esteller
NATURE REVIEWS GENETICS (2007)
Mechanisms of egfr gene transcription modulation:: Relationship to cancer risk and therapy response
Burkhard Brandt et al.
CLINICAL CANCER RESEARCH (2006)
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
S Minucci et al.
NATURE REVIEWS CANCER (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells
LK Gediya et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
ICI182,780 induces p21Waf1 gene transcription through releasing histone deacetylase 1 and estrogen receptor α from Sp1 sites to induce cell cycle arrest in MCF-7 breast cancer cell line
R Varshochi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
DNA topoisomerase II poison TAS-103 transactivates GC-Box-dependent transcription via acetylation of Sp1
T Torigoe et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor α-negative breast cancer cells to tamoxifen
ER Jang et al.
ONCOGENE (2004)
Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of anglogenesis factors
Y Sasakawa et al.
BIOCHEMICAL PHARMACOLOGY (2003)
Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis
L Rössig et al.
CIRCULATION RESEARCH (2002)
Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling
CF Deroanne et al.
ONCOGENE (2002)
Histone deacetylases and cancer: Causes and therapies
PA Marks et al.
NATURE REVIEWS CANCER (2001)
Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase
ZM Lu et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Share Paper
